AbbVie reports revenue growth and raises annual guidance
AbbVie reported $17.404 billion in net revenue for the third quarter of 2026, a 10.3% increase year-over-year. Diluted earnings per share (EPS) was $2.37 on a GAAP basis, and $3.82 on an adjusted basis. The company raised its full-year adjusted EPS guidance to $13.95–$13.99.
Key points
- The 10.3% revenue growth occurred as Humira revenue declined 31.2% to $683 million.
- The annual profit guidance includes a $0.69 per share negative impact from acquired in-process research and development (IPR&D) and milestone expenses.
Financial results and dividends
The 10.3% revenue growth occurred as Humira revenue declined 31.2% to $683 million. The board of directors declared a quarterly dividend increase from $1.73 to $1.82 per share. The new payout takes effect February 16, 2027, for shareholders of record as of January 15, 2027.
During the quarter, the company completed the acquisition of Apogee Therapeutics to develop its immunology pipeline. AbbVie also entered agreements with Valkai and Iambic to integrate artificial intelligence into drug development and accelerate the discovery of new molecules in immunology, neuroscience, and oncology.
Third-quarter financial results
Revenue by quarter, $B
Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.
Risks and outlook
The annual profit guidance includes a $0.69 per share negative impact from acquired in-process research and development (IPR&D) and milestone expenses. Integration costs for the Apogee Therapeutics acquisition are reflected in special reporting items that may affect operating performance.
Key takeaways
Shareholders should track dividend payments in February 2027. Another key metric remains meeting the updated full-year adjusted EPS guidance of $13.95–$13.99, which will be reflected in future financial reports.
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow AbbVie
A notification in your browser or on your phone when we publish about AbbVie. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
